OT mobile menu

Search form


Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

A 47-year-old man presents with an “atrophic” lesion of the skin in the right arm. After a biopsy is performed, what is your diagnosis?

Immune response markers from on-treatment—but not pretreatment—melanoma biopsies predict responses to immune checkpoint blockade.

Patients with metastatic melanoma may benefit from the addition of a local tumor-targeted treatment in addition to ipilimumab.

Obtaining blood biopsies instead of invasive tissue biopsies may be less risky for patients, faster, and cost less.

Along with gene expression signatures from a 15-loci panel, tumor diameter and specific driver mutations predict metastasis risk and survival among patients with uveal melanoma.

In this video we discuss promising results of the anti–PD-L1 agent avelumab in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy.

In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.